Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review.

ABSTRACT:

Background

To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings. This study was conducted due to the need for real-world evidence to complement the findings from controlled clinical phase-III trials.

Methods

A systematic literature search was conducted on March 17, 2024, across 11 databases, utilizing search terms specifically tailored each database. All studies were reviewed qualitatively with specific focus on the outcomes of interest: the best-corrected visual acuity (BCVA), the central retina thickness (CRT), and the burden of therapy.

Results

We identified a total of 22 eligible studies of 1762 eyes from 161

SUBMITTER: Nasimi N 

PROVIDER: S-EPMC11245828 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature